Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study by Mikkelsen, Martin M et al.
RESEARCH ARTICLE Open Access
Insulin resistance, adiponectin and adverse
outcomes following elective cardiac surgery:
a prospective follow-up study
Martin M Mikkelsen
1,2*, Troels K Hansen
3, Jakob Gjedsted
3, Niels H Andersen
4, Thomas D Christensen
1,
Vibeke E Hjortdal
1, Søren P Johnsen
2
Abstract
Background: Insulin resistance and adiponectin are markers of cardio-metabolic disease and associated with
adverse cardiovascular outcomes. The present study examined whether preoperative insulin resistance or
adiponectin were associated with short- and long-term adverse outcomes in non-diabetic patients undergoing
elective cardiac surgery.
Methods: In a prospective study, we assessed insulin resistance and adiponectin levels from preoperative fasting
blood samples in 836 patients undergoing cardiac surgery. Population-based medical registries were used for
postoperative follow-up. Outcomes included all-cause death, myocardial infarction or percutaneous coronary
intervention, stroke, re-exploration, renal failure, and infections. The ability of insulin resistance and adiponectin to
predict clinical adverse outcomes was examined using receiver operating characteristics.
Results: Neither insulin resistance nor adiponectin were statistically significantly associated with 30-day mortality,
but adiponectin was associated with an increased 31-365-day mortality (adjusted odds ratio 2.9 [95% confidence
interval 1.3-6.4]) comparing the upper quartile with the three lower quartiles. Insulin resistance was a poor
predictor of adverse outcomes. In contrast, the predictive accuracy of adiponectin (area under curve 0.75 [95%
confidence interval 0.65-0.85]) was similar to that of the EuroSCORE (area under curve 0.75 [95% confidence interval
0.67-0.83]) and a model including adiponectin and the EuroSCORE had an area under curve of 0.78 [95%
confidence interval 0.68-0.88] concerning 31-365-day mortality.
Conclusions: Elevated adiponectin levels, but not insulin resistance, were associated with increased mortality and
appear to be a strong predictor of long-term mortality. Additional studies are warranted to further clarify the
possible clinical role of adiponectin assessment in cardiac surgery.
Trial Registration: The Danish Data Protection Agency; reference no. 2007-41-1514.
Background
Insulin resistance and circulating levels of adiponectin
are associated with an increased risk of cardiovascular
disease, the metabolic syndrome and a subclinical
inflammatory response in the vascular endothelium
[1,2].
Insulin resistance is a measure of the biological effi-
ciency of the endogenously produced insulin and is pre-
sent when a higher than normal level of insulin is
required in order to maintain normoglycemia. Its preva-
lence in the apparently healthy population is rising [3].
However, it also declines during critical illness and as a
response to surgery [1]. In a recently published study in
patients undergoing cardiac surgery, intraoperative insu-
lin resistance was associated with an increased risk of
short-term adverse outcomes [4]. Moreover, hyperglyce-
mia during cardiopulmonary bypass and preoperative
metabolic syndrome, in which insulin resistance plays a
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morbidity in patients undergoing cardiac surgery [5,6].
Adiponectin, a hormone derived from the adipose tis-
sue, is considered an insulin sensitizer and it upholds
both anti-atherogenic and anti-inflammatory effects
[2,7,8]. In non-healthy individuals, high levels of adipo-
nectin have been associated with an increased cardiovas-
cular disease risk in patients presenting with chest pain,
increased mortality in patients with chronic heart fail-
ure, and predictive of survival after peripheral artery
bypass surgery [9-11].
This strongly indicates that patients with insulin resis-
tance or elevated adiponectin levels may have certain
subclinical features, such as chronic low-grade inflam-
mation, that can increase the risk related to cardiac sur-
gery. Further insights in the relation between metabolic
risk-markers in cardiac surgery could potentially open
new avenues for improving pre-, per-, and postoperative
care, but could also prove useful for preoperative risk
assessment.
Indeed, improvement of risk prediction in cardiac sur-
gery has been requested, as the EuroSCORE overesti-
mates mortality in low-risk patients [12]. We therefore
face a need to address new adverse outcome markers,
including preoperative insulin resistance and adiponec-
tin which have attracted practically no attention con-
cerning preoperative risk prediction in cardiac surgery.
Accordingly, the aim of this study was to examine
whether preoperative insulin resistance or the level of
circulating adiponectin were associated with either
short-term adverse outcomes within 30 days or long-
term adverse outcomes (31-365 days). Secondly, we
aimed to assess if information on these factors may
potentially be useful for risk prediction in non-diabetic
patients undergoing elective cardiac surgery.
Methods
Design and Setting
We conducted a single-center prospective follow-up
study in the Central Denmark Region, which has a
mixed rural-urban population of approximately 1.2 mil-
lion. From 1 April 2005 to 30 September 2007 we
included patients undergoing elective cardiac surgery at
the Department of Cardiothoracic and Vascular Surgery
at Aarhus University Hospital, Skejby, Denmark. The
study complied to the Helsinki declaration and all
patients gave informed consent prior to inclusion. The
study protocol was approved by the Regional Ethics
Committee and the Danish Data Protection Agency
(Reference no. 2007-41-1514).
Study population
Inclusion criteria were i) age older than 18 years, ii)
elective cardiac surgery (surgery performed more than
two days after planning of the procedure) - including
on- and off-pump coronary artery bypass grafting, valve
surgery, thoracic aortic surgery, pulmonary thromben-
darterectomy, grown up congenital heart disease proce-
dures. Exclusion criteria were i) Type I and Type II
diabetes mellitus, ii) fasting blood glucose value above
or equal to 7.0, or iii) previous heart transplant surgery.
During the study period a total of 2,216 patients under-
went cardiac surgery at the department. Patient screen-
ing and recruitment was done by a project nurse
working half-time. Approximately 50% (n = 1193) of the
potential candidates for the study were therefore
screened consecutively. We included 876 patients with
no prior history of diabetes. A preoperative in-hospital
baseline fasting blood sample identified 38 patients with
increased blood glucose levels above the diabetic exclu-
sion criteria. One patient was excluded due to failure of
insulin analysis, and one patient emigrated, leaving 836
patients available for 30-day (short-term) and 31-365
days (long-term) follow-up.
Laboratory analyses
For each participant a preoperative fasting blood sample
was collected (between 6 a.m. and 11 a.m.) and analyzed
at the Department of Clinical Biochemistry, Aarhus Uni-
versity Hospital, Skejby, Denmark, and at the Medical
Research Laboratory, Aarhus University Hospital, Aar-
hus Sygehus, Noerrebrogade, Denmark.
The fasting blood glucose values (mmol/liter) were
measured in duplicate immediately after sampling on
a glucose analyzer (Beckman Instruments, Palo Alto,
CA), and blood insulin values (pmol/liter) were mea-
sured using a commercial immunological kit (DAKO,
Glostrup, Denmark). For insulin, the intraassay coeffi-
cient of variation (CV) was 2.1-3.7%, and the interas-
say CV was 3.4-4.0%. We calculated the insulin
resistance using the homeostasis model assessment
(HOMA), where the calculation of HOMA is based on
the relationship between fasting glucose and insulin
levels.
HOMA Glucose mmol liter Insulin mU liter =× ([ / ] [ / ] ) / . . 22 5
The used constant converting insulin from pmol/liter
to mU/liter was 6.945. Serum adiponectin (mg/liter) was
measured by an in-house time-resolved immunofluoro-
metric assay (R&D Systems, Abingdon, United King-
dom). Intra- and interassay CV averaged less than 5 and
10%, respectively.
Study outcomes
The study outcomes were a composite of i) all-cause
mortality, myocardial infarction or percutaneous coron-
ary intervention (PCI), and stroke, and ii) deep and
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(at the site of bypass graft harvest) and septicemia
(defined as a positive blood culture and/or clinical sep-
sis). We also examined the individual elements of the
composite outcomes, the risk of renal failure (defined as
more than a 100% increase of serum creatinine from
baseline and/or use of dialysis), risk of surgical re-
exploration, as well as the length of stay in the intensive
care unit and the total length of hospital stay.
Since 1968 all Danish residents have been assigned a
unique civil registration number that allows unambigu-
ous record linkage between the Danish health databases.
We used the Danish Registry of Patients and the Wes-
tern Denmark Heart Registry for assessing outcomes.
The Danish National Registry of Patients was established
in 1977 and holds data on all hospitalizations from
somatic Danish hospitals, including dates of admission
and discharge, procedure(s) performed, and up to 20
discharge diagnoses coded by physicians according to
the International Classification of Diseases [8
th revision
(ICD-8) until the end of 1993, end 10
th revision (ICD-
10) thereafter]. Since 1995 discharges from emergency
rooms and outpatient clinics have also been registered
in this registry. The Western Denmark Heart Registry,
established in 1999, is a regional clinical register includ-
ing detailed patient baseline characteristics, data for all
cardiac procedures performed, and per- and postopera-
tive outcomes.
Covariates
Baseline characteristics and in-hospital peroperative data
were collected from a preoperative interview, patient
medical records, the Western Denmark Heart Registry,
the Prescription Database of Central Denmark Region,
and the Danish National Registry of Patients. For each
patient a case-report-form was used.
Baseline data included age, sex, smoking habits, body
mass index, hypertension (defined as systolic pressure
140 mmHg or greater and/or diastolic pressure 90
mmHg or greater), prior ischemic peripheral, cerebro-,
or cardiovascular disease, history of arrhythmias, dia-
betes and dyslipidemia, cardiac ejection fraction, Euro-
SCORE, Charlson Comorbidity Index, glomerular
filtration rate as estimated by the Cockcroft Gault for-
mula (eGFR), serum levels of creatinine, electrolytes,
albumin, fructosamine, white and red blood cell counts,
platelets and the urine albumin creatinine ratio.
The Charlson Comorbidity Index classifies comorbid-
ity and in longitudinal studies it predicts both early and
late mortality [13]. The index was constructed by com-
bining data from the case-report-form with data from
the National Registry of Patients, and for analyses, we
categorized the index score into three levels of comor-
bidity: 0 ("low”), 1-2 ("medium”), and >2 ("high”).
Data from the Western Denmark Heart Registry on
the peroperative covariates included type of operation,
cardiopulmonary bypass time and aortic cross-clamp
time.
From a regional prescription database, we obtained
data regarding the use of medication up to 180 days
preoperatively and 1 year postoperatively. The database
contains data on all redeemed prescriptions at all phar-
macies in the region since 1998. The main variables are
t h eu n i q u ec i v i lr e g i s t r a t i o nn u m b e r ,n a m ea n dd r u g
code, package identifier (enabling identification of
brand, quantity and formulation of the drug), and dates
of refill.
Statistical analyses
Baseline and procedural characteristics are presented as
medians with interquartile ranges or 95% confidence
intervals (95% CI) and categorical data as counts and
frequencies. HOMA and adiponectin were logarithmi-
cally transformed prior to correlation with baseline and
procedural characteristics. Both baseline and procedural
variables were also compared across quartiles of adipo-
nectin and HOMA using the Chi
2 or Kruskal-Wallis test
(data not shown). Based on the quartiles of HOMA and
adiponectin respectively, we divided patients into two
groups. The reference groups consisted of patients with
levels in the three lower quartiles (the adiponectin quar-
tiles with the observed lowest risk) and they were
compared with the upper quartiles of HOMA and adi-
ponectin respectively.
Data on the length of intensive care unit and hospital
stay were analyzed on a logarithmic scale using linear
regression analyses. Thereafter, we transformed the
regression estimate and estimated the absolute differ-
ence in median length of stay between groups at differ-
ent levels of the EuroSCORE. The standard error was
calculated using the delta method. For both short- and
long-term follow-up we constructed cumulative mortal-
ity curves.
The associations between HOMA and adiponectin
groups with both short- and long-term outcomes (indi-
viduals and composites) were examined using multivari-
ate logistic regression analyses, and the associations with
long-term outcomes were also examined using multi-
variate Cox proportional hazard analyses (for all-cause
death and the composite of all-cause death, stroke and
myocardial infarction/PCI) or competing risk regressions
(for stroke, myocardial infarction/PCI, and infections).
In the competing risk regression models, all-cause death
was considered as the potential competing failure event
impeding the non-fatal outcomes of interest. Using the
change-in-estimate method, we examined if adjustment
for possible baseline confounding factors and postopera-
tive time-dependent use of prescribed cardiovascular
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no substantial difference between estimates from the
logistic regressions and Cox or competing risk regres-
sions, results are presented as odds ratios derived from
the logistic regressions. Discrimination analyses and
construction of receiver operating characteristic curves
of both the uni- and multivariate models were per-
formed to assess the predictive values of HOMA and
adiponectin alone and in combination with the Euro-
SCORE. Hosmer-Lemeshow test was used for calibra-
tion analyses. Furthermore, we also included HOMA
and adiponectin as continuous variables in an addi-
tional spline regression analysis in order to identify any
non-linear patterns. A two-tailed p-value less than 0.05
was considered statistically significant. Analyses were
performed using the Stata® 11.0 package (StataCorp LP,
Texas, US).
Results
Study cohort and surgical characteristics
The overall study baseline patient characteristics and
correlations with HOMA and adiponectin are shown in
Table 1. For insulin resistance the upper quartile was
HOMA index levels above 2.6, and for adiponectin the
upper quartile was adiponectin values above 11.7 mg/
liter. HOMA correlated positively with male gender,
body mass index, former myocardial infarction, eGFR,
glucose and insulin as well as the use of beta blockers,
statins and antiplatelets. HOMA was inversely correlated
with adiponectin, the EuroSCORE, microalbuminuria,
type of procedure performed and cross-clamp time, but
showed no correlation with age (Table 1). Adiponectin
correlated positively with age, logistic EuroSCORE,
urine albumin creatinine ratio, level of fructosamine,
time on extra corporal circulation as well as aortic cross
clamp time, and inversely with male gender, body mass
index, former myocardial infarction, eGFR, and the
levels of glucose, insulin and HOMA as well as the use
of beta blockers and statins (Table 1). Moreover,
patients with high HOMA levels had more solitary cor-
onary bypass and less valve procedures performed,
whereas increasing adiponectin levels were correlated
with more valve procedures and less bypass procedures
being performed (Table 1).
Length of stay
There was no difference between the upper quartile and
the three lower quartiles of HOMA regarding median
length of stay in the intensive care unit (difference: 0.02
Table 1 Baseline and peroperative characteristics.
Total
sample
HOMA Adiponectin
Clinical features N = 836 rp -
value
rp -
value
Male gender 607 (73) 0.14 <0.01 -0.32 <0.01
Age (years) 68 [59-75] -0.06 0.08 0.15 <0.01
BMI (kg/(m)
2) 27 [24-30] 0.50 <0.01 -0.38 <0.01
Current smoker 147 (18) <0.01 0.99 -0.06 0.09
Hypertension 465 (56) 0.05 0.18 -0.02 0.50
EF <50% 177 (21) <0.01 0.87 -0.02 0.48
MI 192 (23) 0.12 <0.01 -0.15 <0.01
Stroke 79 (9) 0.06 0.06 0.03 0.33
EuroSCORE 4.4 [2.2-7.8] -0.15 <0.01 0.29 <0.01
Charlson Index 0.05 0.18 0.07 0.05
Low 285 (34)
Medium 432 (52)
High 119 (14)
Paraclinic
Creatinine (mmol/liter) 81 [68-98] 0.03 0.33 <0.01 0.99
UACR (mg/mmol) 0.7 [0.1-1.8] -0.05 0.13 0.16 <0.01
Microalbuminuria 146 (18) -0.08 0.02 0.20 <0.01
eGFR (ml/minute) 81 [61-105] 0.23 <0.01 -0.33 <0.01
Glucose (mmol/liter) 5.4 [5.1-5.8] 0.52 <0.01 -0.19 <0.01
Fructosamine (μmol/
liter)
230 [213-
246]
0.02 0.61 0.21 <0.01
Insulin (pmol/liter) 44 [30-71] 0.99 <0.01 -0.42 <0.01
HOMA 1.6 [1.0-2.6] -0.42 <0.01
Adiponectin (mg/liter) 8.0 [5.6-11.7] -0.42 <0.01
Medicine
RAS inhibitors* 297 (36) 0.08 0.02 -0.01 0.62
Beta blockers 521 (62) 0.14 <0.01 -0.22 <0.01
Statins 526 (63) 0.16 <0.01 -0.23 <0.01
Antiplatelets 337 (40) 0.08 0.02 -0.06 0.07
Procedure
Bypass alone 326 (39) 0.16 <0.01 -0.34 <0.01
Valve alone 258 (31) -0.12 <0.01 0.22 <0.01
Bypass & Valve 131 (16) 0.01 0.81 0.08 0.02
Others 121 (14) -0.07 0.03 0.10 <0.01
Procedure related
ECC (minutes) 91 [68-124] -0.04 0.19 0.14 <0.01
CCT (minutes) 57 [40-79] -0.08 0.01 0.20 <0.01
Data are presented as medians [interquartile range] or absolute numbers (%)
r is the correlation coefficient
* Includes angiotensin-converting enzyme inhibitors and angiotensin-II
receptor antagonists
AF - Atrial fibrillation or flutter; BMI - Body mass index; CCT - Cross clamp
time; ECC - Extra corporal circulation; eGFR - Estimated glomerular filtration
rate; EF - Ejection fraction; HOMA - Homeostasis model assessment; Kg -
Kilogram; M - Meter; MI - Myocardial infarction; UACR - Urinary albumin
creatinine ratio; RAS - Renin angiotensin system
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ence: 0.20 days [95% CI -0.21-0.61]). Patients in the
upper adiponectin quartile stayed 0.15 (95% CI 0.04-0.26)
days longer in the intensive care unit, and had a 0.73
(95% CI 0.27-1.19) days prolonged total hospital stay as
compared to the lower adiponectin quartiles and adjusted
for the logistic EuroSCORE.
Insulin resistance and postoperative adverse outcomes
The associations between HOMA quartiles and study
outcomes at both short- and long-term follow-up are
displayed in Table 2. Increased HOMA values were not
statistically significantly associated with postoperative
mortality when compared to the lower three quartiles
(30-day adjusted OR 1.7 [95% CI 0.5-5.7] and 31-365-
days adjusted OR 1.7 [95% CI 0.7-3.3]) (Figure 1). For
early postoperative infections, the odds ratio was 1.5,
but did not reach statistical significance. Moreover, the
upper HOMA quartile was also not associated with
other individual or combined outcomes. Similarly, com-
paring groups above and below the median HOMA
value showed statistically insignificant associations
between HOMA and outcomes. Furthermore, analyzing
HOMA as a continuous spline function revealed no
specific threshold values in the association with all-
cause death.
Adiponectin and postoperative adverse outcomes
As displayed in Table 3 adiponectin was not associated
with any of the short-term postoperative outcomes,
except from renal failure (adjusted OR 1.8 [95% CI 1.0-
3.3]. In contrast, high levels of circulating adiponectin
were positively associated with all-cause death in the
31-365 days time window (adjusted OR of 2.9 [95% CI
1.3-6.4]) for patients in the upper quartile compared with
patients in the lower three quartiles (Figure 2). The
increased risk of the combined cardiovascular outcome in
the highest adiponectin quartile (adjusted OR 1.7 [95%
CI 0.9-3.1]) was primarily driven by all-cause mortality,
as there were no strong associations between adiponectin
and myocardial infarction/PCI or stroke. Comparing
groups above and below the median adiponectin (data
not shown) indicated an even higher mortality risk
(adjusted OR 4.4 [95% CI 1.6-12.1]). Otherwise, the med-
ian cut-off showed no substantially different trends. Con-
sidered as a continuous variable, each 1 mg/liter increase
in adiponectin was associated with a 1.12 [95% CI 1.08-
1.16] increased adjusted OR for all-cause death. In the
spline regression model we could not determine any spe-
cific cut-off level for adiponectin.
Table 2 Short- and long-term odds ratios considering
insulin resistance.
HOMA quartiles Short-term follow-up
I - III IV Crude Adjusted*
n = 627 n = 209 OR 95% CI OR 95% CI
Death 8 (1.3) 4 (1.9) 1.5 1.0-9.6 1.7 0.5-5.7
MI/PCI 15 (3.4) 5 (3.4) 1.0 0.5-2.8 1.0 0.4-2.8
Stroke 23 (3.7) 8 (3.8) 1.0 0.5-2.4 1.1 0.5-2.5
Renal failure
† 39 (6.2) 16 (7.7) 1.2 0.7-2.3 1.4 0.7-2.7
Re-exploration 54 (8.6) 22 (10.5) 1.2 0.7-2.1 1.3 0.8-2.2
Infections 27 (4.3) 13 (6.2) 1.5 0.7-2.9 1.5 0.8-3.0
CVD composite 44 (7.0) 16 (7.7) 1.1 0.6-2.0 1.1 0.6-2.1
HOMA quartiles Long-term follow-up
I - III IV Crude Adjusted
‡
n = 619 n = 205 OR 95% CI OR 95% CI
Death 20 (3.2) 10 (4.9) 1.5 0.7-3.3 1.7 0.7-3.8
MI/PCI 18 (2.9) 4 (2.0) 0.7 0.2-2.0 0.6 0.2-1.8
Stroke 12 (1.9) 1 (0.5) 0.2 0.1-1.9 0.3 0.1-2.0
Infections 20 (3.2) 8 (3.9) 1.2 0.5-2.8 1.2 0.5-2.9
CVD composite 45 (7.3) 14 (6.8) 0.9 0.5-1.7 0.9 0.5-1.7
* Adjusted for the logistic EuroSCORE
† Adjusted for the logistic EuroSCORE and estimated glomerular filtration rate
‡ Adjusted for the logistic EuroSCORE, Charlson Comorbidity Index and type of
surgery
Short-term is defined as 30-day follow-up
Long-term is defined as follow-up from day 31 until 365
CI - Confidence interval; CVD - Cardiovascular disease; HOMA - Homeostasis
model assessment; MI - Myocardial infarction; OR; - Odds ratio; PCI -
Percutaneous coronary intervention
Figure 1 Cumulative mortality considering HOMA quartiles.
Large graph shows the cumulative mortality from day 31 until 365
(Log rank p > 0.05). Small graph shows the cumulative mortality
from day 0 until 30 (Log rank p> 0.05). x-axes - Days after surgery;
y-axes - Cumulative mortality (%); Dashed lines - Insulin resistance
quartile 4; Solid lines - Insulin resistance quartiles 1-3; HOMA -
Homeostasis model assessment.
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EuroSCORE
The areas under the receiver operating characteristic
curves (AUC) concerning mortality are shown in Table
4. The AUC was 0.84 [95% CI 0.75-0.93] for the logistic
EuroSCORE regarding short-term all-cause death and
0.75 [95% CI 0.67-0.83] for long-term all-cause death.
HOMA did not predict mortality. In contrast, the AUC
for adiponectin was 0.75 [95% CI 0.65-0.85] regarding
long-term mortality and in a model including both the
EuroSCORE and adiponectin the AUC reached 0.78
[95% CI 0.68-0.88]. In a model with only HOMA and
adiponectin a similar AUC was achieved, and when the
EuroSCORE was then added, the AUC increased up to
0.81 [95% CI 0.73-0.89]. Lastly, adding the Charlson
Comorbidity Index to the model further increased the
AUC to 0.86 [95% CI 0.81-0.92]. There were no interac-
tions between sex and insulin resistance or adiponectin
with regard to the risk of any postoperative outcomes.
Hosmer-Lemeshow tests showed acceptable model fit of
the logistic regressions.
Discussion
In the present study, high levels of adiponectin were
associated with an increased 31-365-day mortality fol-
lowing elective cardiac surgery. In addition, adiponectin
had a predictive value corresponding to that of the
EuroSCORE, whereas insulin resistance alone did not
contribute with any important prognostic information
on mortality.
The association between preoperative insulin resis-
tance and short-term mortality (1.7-fold increased risk)
did not reach statistical significance, but seems clini-
cally interesting since high HOMA indices may help
identify a subgroup of non-diabetic patients at higher
risk - and with a possible pre- and intraoperative med-
ical intervention available (i.e. insulin sensitizers and
insulin). A recent study showed an approximately
2-fold increased risk of mortality and major adverse
outcomes in patients with intraoperatively decreased
insulin sensitivity [4]. A low-grade inflammation asso-
ciated with insulin resistance might be accentuated
during surgery, and in particular patients undergoing
cardiac surgery experience aggravated inflammation
and insulin resistance - which participates in a worsen-
ing of endothelial dysfunction, glycemic control, and
increase risk of postoperative adverse outcomes
[14-16]. Moreover, per- and postoperative aggravated
insulin resistance and hyperglycemia are apparently
important factors in studies documenting the effect of
postoperative tight glycemic control with insulin ther-
apy on morbidity and mortality [17,18]. However, not
all studies support the notion that tight intraoperative
glycemic control with insulin therapy reduces adverse
outcomes following cardiac surgery [19]. The present
result showed poor predictive values of preoperatively
measured insulin resistance alone and therefore does
not support the use of routine preoperative assessment
of insulin resistance in cardiac surgery.
Table 3 Short- and long-term odds ratios considering
adiponectin.
Adiponectin quartiles Short-term follow-up
I - III IV Crude Adjusted*
n = 627 n = 209 OR 95% CI OR 95% CI
Death 10 (1.6) 2 (1.0) 0.6 0.4-5.7 0.4 0.1-2.0
MI/PCI 15 (2.4) 5 (2.4) 1.0 0.4-2.8 1.0 0.3-2.7
Stroke 20 (3.2) 11 (5.3) 1.7 0.8-3.6 1.5 0.7-3.3
Renal failure 33 (5.3) 22 (10.5) 2.1 1.2-3.7 1.4 0.7-2.7
Re-exploration 54 (8.6) 22 (10.5) 1.2 0.7-2.1 0.9 0.6-1.9
Infections 29 (4.6) 11 (5.3) 1.1 0.6-2.3 1.0 0.5-2.1
CVD composite 43 (6.9) 17 (8.1) 1.2 0.7-2.2 1.0 0.6-1.9
Adiponectin quartiles Long-term follow-up
I - III IV Crude Adjusted
‡
n = 617 n = 207 OR 95% CI OR 95% CI
Death 13 (2.1) 17 (8.2) 4.2 2.0-8.7 2.9 1.3-6.4
MI/PCI 18 (2.9) 4 (1.9) 0.7 0.2-2.0 0.7 0.2-2.1
Stroke 8 (1.3) 5 (2.4) 1.9 0.6-5.8 1.4 0.4-4.5
Infections 18 (2.9) 10 (4.8) 1.7 0.8-3.7 1.1 0.5-2.6
CVD composite 36 (5.8) 23 (11.1) 2.0 1.2-3.5 1.7 0.9-3.1
* Adjusted for the logistic EuroSCORE
† Adjusted for the logistic EuroSCORE and estimated glomerular filtration rate
‡ Adjusted for the logistic EuroSCORE, Charlson Comorbidity Index and type of
surgery
Short-term is defined as 30-day follow-up
Long-term is defined as follow-up from day 31 until 365
CI - Confidence interval; CVD - Cardiovascular disease; MI - Myocardial
infarction; OR - Odds ratio; PCI - Percutaneous coronary intervention
Figure 2 Cumulative mortality considering adiponectin
quartiles. Large graph shows the cumulative mortality from day 31
until 365 (Log rank p < 0.05). Small graph shows the cumulative
mortality from day 0 until 30 (Log rank p> 0.05). x-axes: Days after
surgery. y-axes: Cumulative mortality (%). Dashed lines: Adiponectin
quartile 4. Solid lines: Adiponectin quartiles 1-3.
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death found in our study is in accordance with the
results reported by Kistorp et al, who found a high adi-
ponectin level to predict mortality in patients with con-
gestive heart failure [10]. Moreover, the “AtheroGene
study”, including 1890 patients with coronary artery dis-
ease, found a positive correlation between adiponectin
levels and the risk of a new cardiovascular event (HR
1.17 for each increase in adiponectin quartile) [20]. In
addition, another study on adiponectin in patients with
coronary artery disease indicated that high adiponectin
levels was associated with an increased risk of cardiovas-
cular death, but when controlled for potential confound-
ing the association did not remain statistically significant
[21]. However, in 2006 results from a metaanalysis indi-
cated that low adiponectin levels were associated with a
higher risk of cardiovascular disease [22]. A bidirectional
association between adiponectin and cardiovascular dis-
ease influenced by the constellation of existing comor-
bidity appears plausible, but the role of adiponectin as a
risk factor or independent prognostic marker in differ-
ent constellations of comorbidities remains contracdic-
tious and sparsely understood [21,23,24].
Preoperative assessment of adiponectin was not asso-
ciated with short-term risk. However, high adiponectin
levels in the present population identified patients with
increased cardiovascular risk on the long term, corre-
sponding to what was achieved by the multifactorial risk
stratification contained in the EuroSCORE.
The EuroSCORE is a sensitive predictor of 30-day
postoperative mortality, but it has been shown to over-
estimate mortality in low-risk patients and to underesti-
mate mortality in high-risk patients [12]. Therefore, it is
important to improve risk prediction both with and
beyond the EuroSCORE (and other alternative risk
assessment tools) by investigating the predictive ability
of new potential markers of risk. In the present study,
neither the HOMA index nor adiponectin levels
assessed in a preoperative fasting blood sample contrib-
uted with better risk prediction regarding the adverse
30-day postoperative outcomes than the EuroSCORE
itself. Nevertheless, our results suggest that preoperative
assessment of especially adiponectin levels may contri-
bute with additional risk stratification and especially
help identify patients with increased long-term risk.
However, since elective cardiac surgery in general is
considered to be safe with a low mortality, a larger
number of patients and morbid events may however be
required to demonstrate improved accuracy of the logis-
tic EuroSCORE from assessment of either insulin resis-
tance or adiponectin.
Limitations and strengths
The study design does not allow us to infer causality
between the insulin resistance, adiponectin and post-
operative outcomes. Even so, we studied a well-defined
cohort that was representative of the patient population
undergoing cardiac surgery at our department. We had
a practically complete follow-up on all included patients,
since our design relied on population-based registries
with complete coverage. Recruitment of participants was
prospective and independent of exposure levels. Besides
that, the levels of insulin resistance and adiponectin
were not known to the surgeons and physicians treating
the patients and therefore the risk of information bias
was minimal. When considering registry data validity,
Table 4 Areas under receiver operating curves characteristics on all-cause death.
Short-term follow-up Long-term follow-up
AUC 95% CI AUC 95% CI
Logistic EuroSCORE 0.84 0.75-0.93 0.75 0.67-0.83
HOMA continuous 0.55 0.36-0.75 0.47 0.34-0.60
HOMA quartiles 0.54 0.40-0.68 0.54 0.46-0.63
ADPN continuous 0.53 0.38-0.68 0.75 0.65-0.85
ADPN quartiles 0.54 0.43-0.65 0.66 0.57-0.76
Logistic EuroSCORE + HOMA continuous 0.84 0.76-0.92 0.77 0.70-0.84
Logistic EuroSCORE + HOMA quartiles 0.77 0.65-0.90 0.76 0.69-0.82
Logistic EuroSCORE + ADPN continuous 0.82 0.68-0.95 0.78 0.68-0.88
Logistic EuroSCORE + ADPN quartiles 0.83 0.70-0.96 0.76 0.68-0.85
HOMA and ADPN continuous 0.77 0.68-0.86
Logistic EuroSCORE
+ HOMA and ADPN continuous
0.81 0.73-0.89
Logistic EuroSCORE
+ HOMA and ADPN continuous + CCI
0.86 0.81-0.92
Short-term is defined as 30-day follow-up
Long-term is defined as follow-up from day 31 until 365
ADPN - Adiponectin; AUC - Area under curve; CI - Confidence interval; CCI - Charlson Comorbidity Index; HOMA - Homeostasis model assessment
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high (approximately 80-99%) for several of the outcomes
in our study including myocardial infarction and stroke
[25,26]. Any misclassification would in any case most
likely be independent of the level of insulin resistance
and adiponectin and would bias the findings toward the
null hypothesis. Although insulin is excreted in a pulsa-
tile fashion, and the average of three independent sam-
ples would be a more precise estimate of the true
plasma insulin value, the use of only one sample is
acceptable and yields similar results compared to three
samples in large datasets [27].
Conclusions
In conclusion, high levels of preoperative insulin resis-
tance or adiponectin are not associated with increased
30-day mortality, but a high level of adiponectin implies
an increased 31-365-day mortality, and slightly pro-
longed length of intensive care unit and total hospital
stay. Owing to our results on prognostic values, we sug-
gest additional studies to further clarify the potentially
important role of preoperative insulin resistance and in
particular adiponectin in preoperative risk assessment in
cardiac surgery.
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